[Pharmacological correction of hypoxic and free-radical disorders in patients with acute myocardial infarction complicated by acute heart failure].
Results of the evaluation of clinical findings in a group of 36 patients with acute myocardial infarction (AMI) complicated by acute heart failure (AHF) of class II - IV [according to T. Killip and J. Kimball (1967)] show that the use of cytoflavin and perftoran favors a decrease in the patient critical situation length, duration of patient's stay in hospital, and lethality level. It is established that these drugs lead to a decrease in the depth of hypoxia and lipid peroxidation in tissues, improves oxygen utilization, and restores antioxidant system activity in AMI/AHF patients.
Livanov
G A
GA
Amagyrov
V P
VP
Batotsyrenov
B V
BV
Lodiagin
A N
AN
Batotsyrenova
Kh V
KhV
D000208:Acute Disease; D003422:Critical Care; D004338:Drug Combinations; D005486:Flavin Mononucleotide / Q000627:therapeutic use; D005466:Fluorocarbons / Q000627:therapeutic use; D005609:Free Radicals / Q000378:metabolism; D006333:Heart Failure / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D000860:Hypoxia / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D007290:Inosine Diphosphate / Q000627:therapeutic use; D007297:Inpatients; D007902:Length of Stay; D015227:Lipid Peroxidation; D009203:Myocardial Infarction / Q000150:complications / Q000188:drug therapy* / Q000401:mortality; D009536:Niacinamide / Q000627:therapeutic use; D013386:Succinates / Q000627:therapeutic use
D004338:Drug Combinations; D005466:Fluorocarbons; D005609:Free Radicals; D013386:Succinates; C507879:cytoflavin; D009536:Niacinamide; D005486:Flavin Mononucleotide; D007290:Inosine Diphosphate; C063334:perftoran